Ignite Creation Date:
2024-05-06 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06131437
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-18
First Post:
2023-11-09
Brief Title:
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Efficacy and Safety of Cagrilintide 24 mg sc in Combination With Semaglutide 24 mg sc CagriSema sc 24 mg24 mg Once-weekly Compared to Tirzepatide 15 mg sc Once-weekly in Participants With Obesity
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide CagriSema is not yet being prescribed by doctors Participant will get injections once a week throughout the treatment period Participant will inject the study medicine under the skin with a pen injector in the thigh stomach or upper arm After a first low dose the study medicine will be gradually increased until reaching the planned dose 24 mg CagriSema or 15 mg Tirzepatide The study will last for about one and a half year for each participant
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U1111-1292-4835 | OTHER | World Health Organization WHO | None |